<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Hepatitis B immune globulin: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Hepatitis B immune globulin: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Hepatitis B immune globulin: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="8520" href="/d/html/8520.html" rel="external">see "Hepatitis B immune globulin: Drug information"</a> and <a class="drug drug_patient" data-topicid="11754" href="/d/html/11754.html" rel="external">see "Hepatitis B immune globulin: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F178933"><span class="drugH1">Brand Names: US</span>
<ul>
<li>HepaGam B;</li>
<li>HyperHEP B;</li>
<li>Nabi-HB</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52867111"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>HepaGam B;</li>
<li>HyperHEP B;</li>
<li>HyperHep B S/D;</li>
<li>HyperHEP B S/D</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F2649544"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Immune Globulin</span></li></ul></div>
<div class="block don drugH1Div" id="F53462466"><span class="drugH1">Dosing: Neonatal</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c3e4dc5b-8846-43dd-b505-cf2fc5bed249">Perinatal exposure, prophylaxis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Perinatal exposure, prophylaxis</b> (CDC, 2005): <b>Note:</b> HBIG may be administered at the same time (but at a different site) or up to 1 month preceding hepatitis B vaccination without impairing the active immune response:</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Neonates born to HBsAg-positive mothers:</i> IM: 0.5 mL as soon after birth as possible (within 12 hours; efficacy decreases significantly if treatment is delayed &gt;48 hours); hepatitis B vaccine series to begin at the same time; if this series is delayed for as long as 3 months, the HBIG dose may be repeated (Saari, 2003)</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Neonates born to mothers with unknown HBsAg status at birth:</i> IM:</p>
<p style="text-indent:-2em;margin-left:4em;">Birth weight &lt;2 kg: 0.5 mL within 12 hours of birth (along with hepatitis B vaccine) if unable to determine maternal HBsAg status within that time</p>
<p style="text-indent:-2em;margin-left:4em;">Birth weight ≥2 kg: 0.5 mL within 7 days of birth while awaiting maternal HBsAg results; if mother is determined to be HBsAg positive, administer dose as soon as possible.</p></div>
</div>
</div>
<div class="block dop drugH1Div" id="F178941"><span class="drugH1">Dosing: Pediatric</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> For exposure prophylaxis, HBIG may be administered at the same time (but at a different site) or up to 1 month preceding hepatitis B vaccination without impairing the active immune response.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c3e4dc5b-8846-43dd-b505-cf2fc5bed249">Perinatal exposure, prophylaxis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Perinatal exposure, prophylaxis</b> (CDC 2005): <i>Infants born to HBsAg-positive mothers:</i> IM: 0.5 mL as a repeat of birth dose if the hepatitis B vaccination series is delayed for as long as 3 months (hepatitis B vaccine should also be administered at the same time/different site)</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="93b60915-33f1-459a-9048-b744eefca8a7">Postexposure prophylaxis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Postexposure prophylaxis: </b></p>
<p style="text-indent:-2em;margin-left:4em;">Infants &lt;12 months: IM: 0.5 mL as soon as possible after exposure (eg, mother or primary caregiver with acute HBV infection); initiate hepatitis B vaccine series</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥12 months and Adolescents: IM: 0.06 mL/kg as soon as possible after exposure (ie, within 24 hours of needlestick, ocular, or mucosal exposure or within 14 days of sexual exposure); repeat at 28 to 30 days after exposure</p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F51112883"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block dohp drugH1Div" id="F51112884"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosing adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doa drugH1Div" id="F178935"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="8520" href="/d/html/8520.html" rel="external">see "Hepatitis B immune globulin: Drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="93b60915-33f1-459a-9048-b744eefca8a7">Postexposure prophylaxis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Postexposure prophylaxis:</b> IM: 0.06 mL/kg as soon as possible after exposure (ie, within 24 hours of needlestick, ocular, or mucosal exposure or within 14 days of sexual exposure); repeat at 28 to 30 days after exposure in non-responders to hepatitis B vaccine or in patients who refuse vaccination</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Postexposure management of health care personnel (HCP) </i>(CDC/ACIP [Schillie 2018]):</p>
<p style="text-indent:-2em;margin-left:6em;">If the HCP has prior documentation of ≥3 doses of a hepatitis B vaccine and a post-vaccination anti-HBs ≥10 milliunits/mL, then HBIG is not needed, regardless of the patients HBsAg status.</p>
<p style="text-indent:-2em;margin-left:6em;">If the HCP is unvaccinated or incompletely vaccinated, and if the source patient is HBsAg positive or their status is unknown, one dose HBIG should be administered. If the source patient is HBsAg negative, then HBIG is not needed.</p>
<p style="text-indent:-2em;margin-left:6em;">If the HCP is vaccinated with 3 doses of hepatitis B vaccine but post-vaccination anti-HBs status is unknown, test HCP for anti-HBs. If anti-HBs ≥10 milliunits/mL then HBIG is not needed. If anti-HBs &lt;10 milliunits/mL, and if the source patient is HBsAg positive or their status is unknown, 1 dose of HBIG should be administered. If anti-HBs &lt;10 milliunits/mL, and if the source patient is HBsAg negative, then HBIG is not needed.</p>
<p style="text-indent:-2em;margin-left:6em;">If the HCP is vaccinated with 6 doses of hepatitis B vaccine but documented as a non-responder to the vaccine, and if the source patient is HBsAg negative, then HBIG is not needed. If the source patient is HBsAg positive or unknown, administer 2 doses of HBIG separated by 1 month.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Postexposure management in nonoccupational settings</i> (CDC [Schillie 2018]): <b>IM:</b></p>
<p style="text-indent:-2em;margin-left:6em;">If the exposed person is in the process of completing the hepatitis B vaccination series and the exposure was to an HBsAg-positive source, administer one dose of HBIG and complete the vaccination series. If exposure was to an HBsAg-unknown source, HBIG treatment is not required but the hepatitis B vaccine series should be completed.</p>
<p style="text-indent:-2em;margin-left:6em;">If the exposed person is unvaccinated and the exposure was to an HBsAg-positive source, administer one dose of HBIG and hepatitis B vaccine as soon as possible (preferably within 24 hours after exposure [&lt;7 days for percutaneous exposure or &lt;14 days for sexual exposure]); complete the vaccination series. If exposure was to an HBsAg-unknown source, HBIG treatment is not required but the hepatitis B vaccine series should be completed.</p>
<p style="text-indent:-2em;margin-left:6em;">If the exposed person has prior documentation of ≥3 doses of a hepatitis B vaccine then HBIG treatment is not required.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="19bf3c78-24e0-4c6a-ac64-5d0d4f061d67">Prevention of hepatitis B virus recurrence after liver transplantation</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Prevention of hepatitis B virus recurrence after liver transplantation (HepaGam B):</b> IV: 20,000 units/dose according to the following schedule:</p>
<p style="text-indent:-2em;margin-left:4em;">Anhepatic phase (Initial dose): One dose (20,000 units) given with the liver transplant</p>
<p style="text-indent:-2em;margin-left:4em;">Week 1 postop: One dose (20,000 units) daily for 7 days (days 1 to 7)</p>
<p style="text-indent:-2em;margin-left:4em;">Weeks 2 to 12 postop: One dose (20,000 units) every 2 weeks starting day 14</p>
<p style="text-indent:-2em;margin-left:4em;">Month 4 onward: One dose (20,000 units) monthly starting on month 4</p>
<p style="text-indent:-2em;margin-left:4em;">Dose adjustment: Adjust dose to reach anti-HBs levels of 500 units/L within the first week after transplantation. In patients with surgical bleeding, abdominal fluid drainage &gt;500 mL or those undergoing plasmapheresis, administer 10,000 units/dose every 6 hours until target anti-HBs levels are reached.</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50991851"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling.</p></div>
<div class="block doha drugH1Div" id="F50989146"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling.</p></div>
<div class="block adr drugH1Div" id="F178914"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Reported with postexposure prophylaxis. Adverse events reported in liver transplant patients included tremor and hypotension, were associated with a single infusion during the first week of treatment, and did not recur with additional infusions.</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:0em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Central nervous system: Headache (14%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Erythema (12%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Hypotension (2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Central nervous system: Malaise (6%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Ecchymoses (2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Nausea (2% to 4%), vomiting (2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Change in WBC count (2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased serum alkaline phosphatase (4%), increased liver enzymes (2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Pain at injection site (4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Myalgia (10%), joint stiffness (2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Increased serum creatinine (2%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%, postmarketing, and/or case reports: Abdominal pain, anaphylactic reaction (rare), angioedema, back pain, chills, diaphoresis, dizziness, dyspnea, fever, flu-like symptoms, hypersensitivity, increased serum lipase, increased serum transaminases, sinus tachycardia, tenderness at injection site, urticaria</p></div>
<div class="block coi drugH1Div" id="F178926"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">HepaGam B: Anaphylactic or severe systemic reaction to human globulin preparations; IgA deficiency; postexposure prophylaxis in patients with severe thrombocytopenia or other coagulation disorders which would contraindicate IM injections (administer only if benefit outweighs the risk).</p>
<p style="text-indent:-2em;margin-left:2em;">HyperHEP B:</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>US labeling:</i> There are no contraindications listed in the US manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Canadian labeling:</i></p>
<p style="text-indent:-2em;margin-left:6em;">HyperHEP B: Hypersensitivity to hepatitis B immune globulin or any component of the formulation; severe thrombocytopenia or other coagulation disorders that would contraindicate IM injections; IgA deficient patients with antibodies against IgA and a history of sensitivity.</p>
<p style="text-indent:-2em;margin-left:6em;">HyperHEP B S/D: Hypersensitivity to hepatitis B immune globulin or any component of the formulation; severe thrombocytopenia or other coagulation disorders that would contraindicate IM injections (administer only if benefit outweighs the risk).</p>
<p style="text-indent:-2em;margin-left:2em;">Nabi-HB: Anaphylactic or severe systemic reaction to human globulin preparations.</p></div>
<div class="block war drugH1Div" id="F178911"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Anaphylaxis/hypersensitivity reactions: Hypersensitivity and anaphylactic reactions can occur; immediate treatment (including epinephrine 1 mg/mL) should be available. Use with caution in patients with isolated immunoglobulin A deficiency or a history of systemic hypersensitivity to human immunoglobulins.</p>
<p style="text-indent:-2em;margin-left:4em;">• Infusion reactions: When administered IV, do not exceed recommended infusion rates; may increase risk of adverse events. Patients should be monitored for adverse events during and after the infusion.</p>
<p style="text-indent:-2em;margin-left:4em;">• Thrombotic events: Thrombotic events have been reported with administration of intravenous immune globulin; use with caution in patients of advanced age, with a history of atherosclerosis or cardiovascular and/or thrombotic risk factors, patients with impaired cardiac output, coagulation disorders, prolonged immobilization, or patients with known/suspected hyperviscosity. Consider a baseline assessment of blood viscosity in patients at risk for hyperviscosity.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Bleeding disorders: Use with caution in patients with thrombocytopenia or coagulation disorders; IM injections may be contraindicated.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Human plasma: Product of human plasma; may potentially contain infectious agents which could transmit disease. Screening of donors, as well as testing and/or inactivation or removal of certain viruses, reduces the risk. Infections thought to be transmitted by this product should be reported to the manufacturer.</p>
<p style="text-indent:-2em;margin-left:4em;">• Maltose: Some products may contain maltose, which may result in falsely-elevated blood glucose readings.</p>
<p style="text-indent:-2em;margin-left:4em;">• Polysorbate 80: Some dosage forms may contain polysorbate 80 (also known as Tweens). Hypersensitivity reactions, usually a delayed reaction, have been reported following exposure to pharmaceutical products containing polysorbate 80 in certain individuals (Isaksson 2002; Lucente 2000; Shelley 1995). Thrombocytopenia, ascites, pulmonary deterioration, and renal and hepatic failure have been reported in premature neonates after receiving parenteral products containing polysorbate 80 (Alade 1986; CDC 1984). See manufacturer’s labeling.</p></div>
<div class="block foc drugH1Div" id="F178920"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Injection: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">HepaGam B: 312 units/mL (1 mL) [contains polysorbate 80]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Injection [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">HepaGam B: 312 units/mL (1 mL, 5 mL) [contains polysorbate 80]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intramuscular: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">HyperHEP B:  (0.5 mL, 1 mL, 5 mL)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Nabi-HB:  (1 mL, 5 mL) [thimerosal free; contains polysorbate 80]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intramuscular [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Nabi-HB:  (1 mL, 5 mL) [contains polysorbate 80]</p></div>
<div class="block geq drugH1Div" id="F178907"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F56316784"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (HepaGam B Injection)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">312 units/mL (per mL): $244.02</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (HyperHEP B Intramuscular)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">220 units/mL (per mL): $192.06</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Nabi-HB Intramuscular)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">312 units/mL (per mL): $200.26</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution Prefilled Syringe</b> (HyperHEP B Intramuscular)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">110 units/0.5 mL (per 0.5 mL): $106.14</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">220 units/mL (per mL): $200.15</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52867112"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Injection: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">HepaGam B: 312 units/mL (1 mL, 5 mL) [contains polysorbate 80]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intramuscular: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">HyperHEP B: 220 units/mL (1 mL, 5 mL)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">HyperHep B S/D: 217 units/mL (0.5 mL, 1 mL, 5 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Prefilled Syringe, Intramuscular: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">HyperHEP B: 110 units/0.5 mL (0.5 mL)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">HyperHEP B S/D: 110 units/0.5 mL (0.5 mL)</p></div>
<div class="block admp drugH1Div" id="F52612977"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">IM: Inject only in the anterolateral aspects of the upper thigh or the deltoid muscle; multiple injections may be necessary when the dosage is a large volume (postexposure prophylaxis). Do not administer hepatitis vaccine and HBIG in same syringe (vaccine will be neutralized); hepatitis vaccine may be administered at the same time at a separate site</p></div>
<div class="block adm drugH1Div" id="F178923"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">HBIG may be administered at the same time (but at a different site) or up to 1 month preceding hepatitis B vaccination without impairing the active immune response.</p>
<p style="text-indent:-2em;margin-left:2em;">IM: Post-exposure prophylaxis: IM injection only in anterolateral aspect of upper thigh and deltoid muscle of upper arm; to prevent injury from injection, care should be taken when giving to patients with thrombocytopenia or bleeding disorders.</p>
<p style="text-indent:-4em;margin-left:4em;">IV:</p>
<p style="text-indent:-2em;margin-left:4em;">HepaGam B: Liver transplant: Administer at 2 mL/minute. Decrease infusion to ≤1 mL/minute for patient discomfort or infusion-related adverse events. Actual volume of infusion is dependent upon potency labeled on each individual vial.</p>
<p style="text-indent:-2em;margin-left:4em;">Nabi-HB: Although not FDA-approved for this purpose, Nabi-HB has been administered intravenously in hepatitis B-positive liver transplant recipients (Dickson 2006).</p></div>
<div class="block sts drugH1Div" id="F178932"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:0em;display:inline">Refrigerate at 2°C to 8°C (36°F to 46°F); do not freeze. Do not shake vial; avoid foaming. Extended storage information at room temperature may be available; contact product manufacturer to obtain current recommendations.</p>
<p style="text-indent:-2em;margin-left:2em;">HepaGamB; Nabi-HB: Use within 6 hours of entering vial.</p></div>
<div class="block usep drugH1Div" id="F53567187"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Parenteral:</p>
<p style="text-indent:-2em;margin-left:2em;">IM: HepaGam B, HyperHEP B S/D, Nabi-HB: Provide prophylactic postexposure passive immunity to hepatitis B following perinatal exposure of infants born to HBsAg-positive mothers (FDA approved in neonates and infants); provide prophylactic postexposure passive immunity to hepatitis B following acute exposure to blood containing hepatitis B surface antigen (HBsAg), sexual exposure to HBsAg-positive persons, or household exposure to persons with acute HBV infection (FDA approved in infants, children, and adults)</p>
<p style="text-indent:-2em;margin-left:2em;">IV: HepaGam B: Prevention of hepatitis B virus recurrence after liver transplantation in HBsAg-positive transplant patients (FDA approved in adults)</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> Hepatitis B immune globulin is not indicated for treatment of active hepatitis B infection and is ineffective in the treatment of chronic active hepatitis B infection.</p></div>
<div class="block mst drugH1Div" id="F6052749"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">HBIG may be confused with BabyBIG</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">International issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Bayhep-B [Philippines, Turkey] may be confused with Bayrab which is a brand name for rabies immune globulin [Philippines, Turkey]; Bayrho-D which is brand name for Rh<sub>o</sub>D immune globulin [Israel, Turkey] </p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13299441"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F178915"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Efgartigimod Alfa: May diminish the therapeutic effect of Fc Receptor-Binding Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rozanolixizumab: May diminish the therapeutic effect of Fc Receptor-Binding Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vaccines (Live): Immune Globulins may diminish the therapeutic effect of Vaccines (Live).  Management: Live organism vaccination should be withheld for as long as 6 to 11 months following immune globulin administration. Recommendations vary by product and immune globulin dose, see full monograph for details.<i> Risk D: Consider therapy modification</i></p></div>
<div class="block pri drugH1Div" id="F2530309"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Use of hepatitis immune globulin (HBIG) in pregnant patients following accidental or occupational exposure to hepatitis B virus should be the same as in nonpregnant persons. HBIG should not be administered to pregnant patients with hepatitis B infection to reduce the risk of neonatal infection (ACOG 2023).</p></div>
<div class="block mopp drugH1Div" id="F53567145"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Liver transplant patients: anti-HB levels; infusion-related adverse events</p></div>
<div class="block pha drugH1Div" id="F178910"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Hepatitis B immune globulin (HBIG) is a nonpyrogenic sterile solution containing immunoglobulin G (IgG) specific to hepatitis B surface antigen (HBsAg). HBIG differs from immune globulin in the amount of anti-HBs. Immune globulin is prepared from plasma that is not preselected for anti-HBs content. HBIG is prepared from plasma preselected for high titer anti-HBs. In the US, HBIG has an anti-HBs high titer &gt;1:100,000 by IRA.</p></div>
<div class="block phk drugH1Div" id="F178925"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Duration: Postexposure prophylaxis: 3 to 6 months</p>
<p style="text-indent:-2em;margin-left:2em;">Absorption: IM: Slow</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life: 17 to 25 days</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>d</sub>: 7 to 15 L</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak, serum: IM: 2 to 10 days</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F178928"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Hepatect | Hepatitis b immunoglobulin | Hepuman</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Hepatect | Uman big</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Hepatitis b immunoglobulin</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Neohepatect</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Hepatect cp</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Hepatect | Niuliva</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Igantibe</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Hepatitis b ig. | Hepatitis b immun | Hepatitis b immuno | Human Hepatitis B Immunoglobulin</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Hepatect cp | Hepuman | Hyperhep b | Immunohbs | Niuliva</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Hepatect | Human antihep.b | Neohepatect</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Aunativ | Fovepta | Hepatect | Hepatect cp | Hepatitis b immunglobulin | Umanbig</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Hepuman</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Hepatitis b immunoglobulin behring | Hepatitis b immunoglobulin p Behring | Uman big</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Hepabig</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Gamma anti-hepatitis B | Hepatect | Hepuman</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Hepatect</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Hepatect cp | Ivhebex | Zutectra</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Hepatect cp | Hepatitis b ig | ImmunoGam</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Aunativ s.d. | Hepatect cp | Hepatitis b immunoglobulin</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Hepatect | Hepuman</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Imunoglobulin protiv hepatitisa B</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Hepatect | Umanbig</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Bayhep | Hepatitis b immunoglobulin | Hepbquin</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Fovepta | Hepa bsv | Hepabig | Samhep</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Haimabig | Hepuman b | Igantibe | Immunohbs | Keyvenb | Neohepatect | Uman big</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">H big abbott | H big mitsubishi | Hb Globulin | Hebsbulin ih | Hepatothera | Hepatothera fujisawa</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Hepabig | Hepabulin sn | Iv hepabulin sn</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Hepuman</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Hepaga b | Hepatect cp | Keyvenb</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Hepaga b</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Immunohbs</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">H-Big | Hepabig | Hepuman berna | Igantibe</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Hepatitis b | Hepbquin</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Aunativ | Hepatect | Hepatect cp | Hepatitis b immunoglobulin p Behring | Omri-hep-b | Umanbig</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Hepatitis b immunoglobulin</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Fovepta</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Hepabig | Hepuman</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Bayhep B | Hepatect | Hepatitis b immunoglobulin | Hyperhep b</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Gamma anty hbs | Hepatect | Hepatect cp | Niuliva | Uman big</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Bayhep B | Hepagam b | Nabi-hb</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Gammaglobulina antihepatitis-B P Behring | Hepatect | Hepatect cp | Hepuman berna | Uman big</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Hepatect CP</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Hepatect cp</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Antihep | Hepatect | Neohepatect</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Aunative | Fovepta | Hepagam b | Hepatect | Hepuman</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Aunativ | Neohepatect | Umanbig</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Bayhep B | Hyperhep B S/D</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Aunativ | Hepatect | Neohepatect | Pasteurised Human Antihepatitis B Immunogl. G</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Hbig | Hepatect | Hepuman berna | Human Hepatitis B Immunoglobulin | Igantibe | Immunohbs</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Aunativ | Hepatect | Immuno hbs</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Bayhep B | Hepagam b | Hepatect | Hepatitis b immune globulin | Hepatitis b immunoglobulin p | Hepuman | Hyperhep b | Ivhebex</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Bayhep B | Hepatect | Hepatitis b ig p | Hepatitis b immunoglobulin p</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Anti b cp | Igantibe</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Hebagam</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-21678611">
<a name="21678611"></a>Agarwal S, Karmaus W, Davis S, Gangur V. Immune markers in breast milk and fetal and maternal body fluids: a systematic review of perinatal concentrations. <i>J Hum Lact</i>. 2011;27(2):171-186.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hepatitis-b-immune-globulin-pediatric-drug-information/abstract-text/21678611/pubmed" id="21678611" target="_blank">21678611</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3960626">
<a name="3960626"></a>Alade SL, Brown RE, Paquet A Jr. Polysorbate 80 and E-Ferol toxicity. <i>Pediatrics</i>. 1986;77(4):593-597.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hepatitis-b-immune-globulin-pediatric-drug-information/abstract-text/3960626/pubmed" id="3960626" target="_blank">3960626</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-37590986">
<a name="37590986"></a>American College of Obstetricians and Gynecologists (ACOG). Viral hepatitis in pregnancy: ACOG clinical practice guideline no. 6.<i> Obstet Gynecol</i>. 2023;142(3):745-759. doi:10.1097/AOG.0000000000005300<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hepatitis-b-immune-globulin-pediatric-drug-information/abstract-text/37590986/pubmed" id="37590986" target="_blank">37590986</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6423951">
<a name="6423951"></a>Centers for Disease Control (CDC). Unusual syndrome with fatalities among premature infants: association with a new intravenous vitamin E product. <i>MMWR Morb Mortal Wkly Rep</i>. 1984;33(14):198-199. <a href="https://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm" target="_blank">http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm</a>.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hepatitis-b-immune-globulin-pediatric-drug-information/abstract-text/6423951/pubmed" id="6423951" target="_blank">6423951</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Centers for Disease Control and Prevention (CDC), “A Comprehensive Immunization Strategy to Eliminate Transmission of Hepatitis B Virus Infection in the United States: Recommendations of the Advisory Committee on Immunization Practices (ACIP) Part I: Immunization of Infants, Children, and Adolescents,” <i>MMWR Recomm Rep</i>, 2005, 54(RR-16):1-31.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11442229">
<a name="11442229"></a>Centers for Disease Control and Prevention (CDC), U.S. Public Health Service, "Updated U.S. Public Health Service Guidelines for the Management of Occupational Exposures to HBV, HCV, and HIV and Recommendations for Postexposure Prophylaxis," <i>MMWR Recomm Rep</i>, 2001, 50(RR-11):1-52.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hepatitis-b-immune-globulin-pediatric-drug-information/abstract-text/11442229/pubmed" id="11442229" target="_blank">11442229</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17687059">
<a name="17687059"></a>Cohen V, Jellinek SP, Teperikidis L, et al, “Room-Temperature Storage of Medications Labeled for Refrigeration,” <i>Am J Health-Syst Pharm</i>, 2007, 64(16):1711-15.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hepatitis-b-immune-globulin-pediatric-drug-information/abstract-text/17687059/pubmed" id="17687059" target="_blank">17687059</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16382463">
<a name="16382463"></a>Dickson RC, Terrault NA, Ishitani M, et al, “Protective Antibody Levels and Dose Requirements for IV 5% Nabi Hepatitis B Immune Globulin Combined With Lamivudine in Liver Transplantation for Hepatitis B-Induced End Stage Liver Disease,” <i>Liver Transpl</i>, 2006, 12(1):124-33. doi: 10.1002/lt.20582.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hepatitis-b-immune-globulin-pediatric-drug-information/abstract-text/16382463/pubmed" id="16382463" target="_blank">16382463</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  HepaGam B (hepatitis B immune globulin intravenous [human]) [prescribing information]. Roswell, GA: Saol Therapeutics Inc; March 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-HepaGam.2">
<a name="HepaGam.2"></a>HepaGam B (hepatitis B immune globulin intravenous [human]) [product monograph]. Vaughan, Ontario, Canada: Accuristix; October 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-HyperHEPB.1">
<a name="HyperHEPB.1"></a>HyperHEP B (hepatitis B immune globulin intravenous [human]) [prescribing information]. Research Triangle Park, NC: Grifols Therapeutics LLC; August 2022.</div>
</li>
<li>
<div class="reference">
                  HyperHEP B (hepatitis B immune globulin intravenous [human]) [product monograph]. Mississauga, Ontario, Canada: Grifols Canada Ltd; September 2021.</div>
</li>
<li>
<div class="reference">
                  HyperHEP B S/D (hepatitis B immune globulin [human]) [product monograph]. Mississauga, Ontario, Canada: Grifols Canada Ltd; February 2012.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12534540">
<a name="12534540"></a>Isaksson M, Jansson L. Contact allergy to Tween 80 in an inhalation suspension. <i>Contact Dermatitis</i>. 2002;47(5):312-313.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hepatitis-b-immune-globulin-pediatric-drug-information/abstract-text/12534540/pubmed" id="12534540" target="_blank">12534540</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10985636">
<a name="10985636"></a>Lucente P, Iorizzo M, Pazzaglia M. Contact sensitivity to Tween 80 in a child. <i>Contact Dermatitis</i>. 2000;43(3):172.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hepatitis-b-immune-globulin-pediatric-drug-information/abstract-text/10985636/pubmed" id="10985636" target="_blank">10985636</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Nabi-HB (hepatitis B immune globulin intravenous [human]) [prescribing information]. Boca Raton, FL: ADMA Biologics; October 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12837889">
<a name="12837889"></a>Saari TN and American Academy of Pediatrics Committee on Infectious Diseases, "Immunization of Preterm and Low Birth Weight Infants. American Academy of Pediatrics Committee on Infectious Diseases," <i>Pediatrics</i>, 2003, 112(1 Pt 1):193-8.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hepatitis-b-immune-globulin-pediatric-drug-information/abstract-text/12837889/pubmed" id="12837889" target="_blank">12837889</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Schillie S, Vellozzi C, Reingold A, et al. Prevention of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices. <i>MMWR Recomm Rep.</i> 2018;67(No. RR-1):1-31. doi: 10.15585/mmwr.rr6701a1.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7746084">
<a name="7746084"></a>Shelley WB, Talanin N, Shelley ED. Polysorbate 80 hypersensitivity. <i>Lancet</i>. 1995;345(8980):1312-1313.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hepatitis-b-immune-globulin-pediatric-drug-information/abstract-text/7746084/pubmed" id="7746084" target="_blank">7746084</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16231258">
<a name="16231258"></a>Tung BY and Kowdley KV, “Hepatitis B and Liver Transplantation,” <i>Clin Infect Dis</i>, 2005, 41(10):1461-6.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hepatitis-b-immune-globulin-pediatric-drug-information/abstract-text/16231258/pubmed" id="16231258" target="_blank">16231258</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 13229 Version 243.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
